Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 10, 837

Clinical Relevance of Genetic Analysis in Patients With Pituitary Adenomas: A Systematic Review


Clinical Relevance of Genetic Analysis in Patients With Pituitary Adenomas: A Systematic Review

Medard F M van den Broek et al. Front Endocrinol (Lausanne).


Pituitary adenomas (PA) are amongst the most prevalent intracranial tumors, causing complications by hormonal overproduction or deficiency and tumor mass effects, with 95% of cases occurring sporadically. Associated germline mutations (AIP, MEN1, CDKN1B, PRKAR1A, SDHx) and Xq26.3 microduplications are increasingly identified, but the clinical consequences in sporadic PA remain unclear. This systematic review evaluates predictors of a genetic cause of sporadic PA and the consequences for treatment outcome. We undertook a sensitive MEDLINE/Pubmed, EMBASE, and Web of Science search with critical appraisal of identified studies. Thirty-seven studies on predictors of mutations and 10 studies on the influence on treatment outcome were included. AIP and MEN1 mutations were associated with young age of PA diagnosis. AIP mutations were also associated with gigantism and macroadenomas at time of diagnosis. Xq26.3 microduplications were associated with PA below the age of five. AIP and MEN1 mutation analysis is therefore recommended in young patients (≤30 years). AIP mutation analysis is specifically recommended for patients with PA induced gigantism and macroadenoma. Screening for Xq26.3 microduplications is advisable in children below the age of five with increased growth velocity due to PA. There is no evidence supporting mutation analysis of other genes in sporadic PA. MEN1 mutation related prolactinoma respond well to dopamine agonists while AIP mutation associated somatotroph and lactotroph adenoma are frequently resistant to medical treatment. In patients harboring an Xq26.3 microduplication treatment is challenging, although outcome is not different from other patients with PA induced gigantism. Effective use of genetic analysis may lead to early disease identification, while knowledge of the impact of germline mutations on susceptibility to various treatment modalities helps to determine therapeutic strategies, possibly lowering disease morbidity.

Keywords: genetic analysis; germline mutation; mutation; pituitary adenoma; screening.


Figure 1
Figure 1
Flowchart. a: original records. Records can be included for both clinical questions (predictors of germline mutations, treatment outcome). b: GPR101 allelic variants, GNAI1/2/3, CABLES1, KCNQ1/2, genome wide association studies, SNP allele frequencies studies.

Similar articles

See all similar articles


    1. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, et al. . The prevalence of pituitary adenomas: a systematic review. Cancer. (2004) 101:613–9. 10.1002/cncr.20412 - DOI - PubMed
    1. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas : a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. (2006) 91:4769–75. 10.1210/jc.2006-1668 - DOI - PubMed
    1. Fontana E, Gaillard R. Epidémiologie des adénomes hypophysaires: étude dans une agglomération urbaine de Suisse. Rev Med Suisse. (2009) 5:2172–4. - PubMed
    1. Fernandez A, Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol. (2010) 72:377–82. 10.1111/j.1365-2265.2009.03667.x - DOI - PubMed
    1. Raappana A, Koivukangas J, Ebeling T, Pirilä T. Incidence of pituitary adenomas in northern Finland in 1992-2007. J Clin Endocrinol Metab. (2010) 95:4268–75. 10.1210/jc.2010-0537 - DOI - PubMed

Publication types